| 1126 |
decreased |
protein import into nucleus, translocation
(GO:0000060)
|
androgen receptor
(PR:000004191)
|
2393: Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced
|
| 1127 |
decreased |
regulation of DNA binding
(GO:0051101)
|
androgen
(CHEBI:50113)
|
2393: Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced
|
| 329 |
increased |
|
Amputation, Congenital
(MESH:C565682)
|
591: Increased, amputations
|
| 1035 |
increased |
|
alpha-beta T cell receptor complex
(GO:0042105)
|
None
|
| 1036 |
increased |
gene conversion
(GO:0035822)
|
alpha-beta T cell receptor complex
(GO:0042105)
|
None
|
| 1052 |
occurrence |
gene conversion
(GO:0035822)
|
alpha-beta T cell receptor complex
(GO:0042105)
|
2253: Gluten-reactive T cell receptors, generation
|
| 1151 |
abnormal |
Abnormality of cellular immune system
(HP:0010987)
|
alpha-beta T cell
(CL:0000789)
|
2324: Increased of Treg/Th17 cell ratio
|
| 435 |
decreased |
signaling
(GO:0023052)
|
alpha-2A adrenergic receptor
(PR:000001186)
|
849: Inhibition, Antgonism of NE receptor
|
| 1113 |
decreased |
G-protein coupled receptor signaling pathway
(GO:0007186)
|
alpha-1A adrenergic receptor
(PR:000001183)
|
2370: Agonism binding, α1-Adrenoreceptor
|
| 1060 |
decreased |
retinoic acid biosynthetic process
(GO:0002138)
|
all-trans-retinoic acid
(CHEBI:15367)
|
1881: Decreased, all-trans retinoic acid (atRA) concentration
|
| 486 |
decreased |
catalytic activity
(GO:0003824)
|
AKT kinase
(PR:000029189)
|
973: KE5 : Decrease, AKT/eNOS activity
|
| 1148 |
occurrence |
Amyotrophic lateral sclerosis
(HP:0007354)
|
adult central nervous system
(UBERON:6003623)
|
2416: human amyotrophic lateral sclerosis (ALS)
|
| 1108 |
increased |
Endometrial carcinoma
(HP:0012114)
|
adenosquamous carcinoma
(MESH:D018196)
|
1070: Increased, adenosquamous carcinomas of endometrium
|
| 558 |
increased |
|
adenosquamous carcinoma
(MESH:D018196)
|
1070: Increased, adenosquamous carcinomas of endometrium
|
| 567 |
increased |
Pituitary adenoma
(HP:0002893)
|
Adenoma
(MESH:D000236)
|
1082: Increased, adenomas (pituitary)
|
| 366 |
increased |
|
Adenoma
(MESH:D000236)
|
9 Events
|
| 410 |
increased |
Carcinoma, Renal Cell
(MESH:D002292)
|
Adenoma
(MESH:D000236)
|
713: Increase, Adenomas/carcinomas (renal tubular)
|
| 413 |
increased |
hepatocellular carcinoma
(MESH:D006528)
|
Adenoma
(MESH:D000236)
|
719: Increase, hepatocellular adenomas and carcinomas
|
| 174 |
increased |
gene expression
(GO:0010467)
|
acyl-CoA desaturase
(PR:000014497)
|
2 Events
|
| 943 |
increased |
acute-phase response
(GO:0006953)
|
Acute phase proteins
(N/A)
|
2 Events
|
| 730 |
decreased |
activin receptor signaling pathway
(GO:0032924)
|
activin receptor complex
(GO:0048179)
|
None
|
| 729 |
decreased |
activin receptor signaling pathway
(GO:0032924)
|
activin complex
(GO:0048180)
|
None
|
| 1152 |
disrupted |
Abnormality of cellular immune system
(HP:0010987)
|
activated CD8-positive, alpha-beta T cell
(CL:0000906)
|
2326: CTL cytotoxic activity disruption
|
| 982 |
decreased |
impaired synaptic plasticity
(MP:0001900)
|
actin cytoskeleton of dendritic spine
(GO:0098938)
|
None
|
| 1101 |
decreased |
dendritic spine morphogenesis
(GO:0060997)
|
actin cytoskeleton
(GO:0015629)
|
2078: Loss of drebrin
|